Pickering Grant: insider trades.
Pickering Grant reported 10 non-derivative transactions on 3 SEC ownership filings in Q3 2026: 0 open-market purchases and 6 sales ($1.0M), across 1 company.
- Transactions
- 10
- Purchases (P)
- 0
- Sales (S)
- 6
- Companies
- 1
- Name as filed
- PICKERING GRANT
Companies
| Company | Relationship | Transactions |
|---|---|---|
| Vaxcyte, Inc. (PCVX) | Director, Officer · CHIEF EXECUTIVE OFFICER | 10 |
Transactions
| Date | Company | Code | Shares | Price | Owned after | Filing |
|---|---|---|---|---|---|---|
| 2026-09-08 | Vaxcyte, Inc. | F | 17,056 | $60.36 | 429,902 | Form 4 |
| 2026-09-02 | Vaxcyte, Inc. | F | 3,427 | $61.58 | 446,958 | Form 4 |
| 2026-08-31 | Vaxcyte, Inc. | F | 2,862 | $60.74 | 450,385 | Form 4 |
| 2026-07-27 | Vaxcyte, Inc. | M | 16,198 | $2.03 | 469,445 | Form 4 |
| 2026-07-27 | Vaxcyte, Inc. | S | 622 | $55.54 | 133,593 | Form 4 |
| 2026-07-27 | Vaxcyte, Inc. | S | 244 | $55.96 | 133,215 | Form 4 |
| 2026-07-27 | Vaxcyte, Inc. | S | 756 | $55.52 | 133,459 | Form 4 |
| 2026-07-27 | Vaxcyte, Inc. | S | 4,415 | $55.93 | 453,247 | Form 4 |
| 2026-07-27 | Vaxcyte, Inc. | S | 11,783 | $55.52 | 457,662 | Form 4 |
| 2026-07-27 | Vaxcyte, Inc. | S | 378 | $55.91 | 133,215 | Form 4 |
Questions
What stock did Pickering Grant buy or sell?
Pickering Grant reported 10 non-derivative transactions on 3 SEC ownership filings in Q3 2026: 0 open-market purchases and 6 sales ($1.0M), across 1 company.
Is Pickering Grant the same person as other filers with this name?
This page covers SEC CIK 1258693 only. The SEC assigns each reporting owner a CIK, and people with the same name have different CIKs.
Source: SEC Insider Transactions Data Sets, Q3 2026. Reported as filed; we do not assess intent, performance or compliance. All filings for this CIK on SEC.gov.
Plain-text version for agents and LLMs: /insiders/pickering-grant-1258693.md
Independent. Not affiliated with, endorsed by, or sponsored by the U.S. Securities and Exchange Commission. Data is reproduced from public SEC filings and datasets. Not investment advice.